Abstract
The availability of recombinant follicle-stimulating hormone (FSH) and luteinizing hormone (LH) opens an opportunity to individualize ovarian stimulation. While the need for FSH in ovarian stimulation is universal, a question remains whether exogenous LH is beneficial. Previous population-based research showed that added LH is indicated in elderly and in profoundly LH depressed patients. This commentary explores potential individual patient parameters that may hint that this specific individual may prospectively need supplemented LH, irrespective of her age or experience from previous cycles. Specifically, it is suggested that in an antagonist protocol, the degree of LH recovery 24 h post first GnRH antagonist injection can identify those patients who may benefit from added LH. In addition, rising LH during the first 5 days of stimulation may predispose patients to a sharp LH drop following the first GnRH antagonist dose, and the need for added LH.
References
1.
Alviggi
C
, Conforti
A
, Esteves
SC
, Andersen
CY
, Bosch
E
, Bühler
K
, et al Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review
. Fertil Steril
. 2018
;109
:644
–64
. 2.
Mochtar
MH
, Danhof
NA
, Ayeleke
RO
, Van der Veen
F
, van Wely
M
. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles
. Cochrane Database Sys Rev
. 2017
;24
:5
. 3.
Conforti
A
, Esteves
SC
, Di Rella
F
, Strina
I
, De Rosa
P
, Fiorenza
A
, et al The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis
. Reprod Biol Endocrinol
. 2019
;17
:18
. 4.
The Ganirelix Dose-Finding Study Group
. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon)
. Hum Reprod
. 1998
;13
:3023
–31
.5.
Huirne
JA
, van Loenen
AC
, Schats
R
, McDonnell
J
, Hompes
PG
, Schoemaker
J
, et al Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy
. Hum Reprod
. 2005
;20
:359
–67
. 6.
Kol
S
. To add or not to add LH: consideration of LH concentration changes in individual patients
. Reprod Biomed Online
. 2005
;11
;664
–6
. 7.
Kol
S
, Homburg
R
. Change, change, change: hormonal actions depend on changes in blood levels
. Human Reproduction
. 2008
;23
:1004
–6
. 8.
Duijkers
IJ
, Klipping
C
, Willemsen
WN
, Krone
D
, Schneider
E
, Niebch
G
, et al Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers
. Human Reproduction
. 1998
;13
:2392
–8
. 9.
Kol
S
. Individualized treatment from theory to practice: the private case of adding LH during GnRH antagonist-based stimulation protocol
. Clin Med Insights Reprod Health
. 2014
;14
:59
–64
.10.
Blockeel
C
, Sterrenburg
MD
, Broekmans
FJ
, Eijkemans
MJ
, Smitz
J
, Devroey
P
, et al Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5
. J Clin Endocrinol and Metab
. 2011
;96
;1122
–8
. 11.
Kolibianakis
EM
, Albano
C
, Kahn
J
, Camus
M
, Tournaye
H
, Van Steirteghem
AC
, et al Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy
. Fertil Steril
. 2003
;79
:873
–80
. 12.
Hershkop
E
, Segal
L
, Fainaru
O
, Kol
S
. “Model” versus “everyday” patients: can randomized controlled trial data really be applied to the clinic?
Reprod Biomed Online
. 2017
;34
:274
–9
. 13.
Vanetik
S
, Beck-Fruchter
R
, Segal
L
, Kol
S
. The Importance of mid-follicular phase luteinizing hormone rise in GnRH antagonist-based ovarian stimulation for IVF
. Gynecol Obstet Invest
. 2020
;11
:1
–5
.14.
de Koning
J
. Gonadotrophin surge-inhibiting/attenuating factor governs luteinizing hormone secretion during the ovarian cycle: physiology and pathology
. Hum Reprod
. 1995
;10
:2854
–61
. 15.
Fowler
PA
, Sorsa-Leslie
T
, Harris
W
, Mason
HD
. Ovarian gonadotrophin surge-attenuating factor (GnSAF): where are we after 20 years of research?
Reproduction
. 2003
;126
:689
–99
. 16.
Jaakkola
T
, Ding
YQ
, Kellokumpu-Lehtinen
P
, Valavaara
R
, Martikainen
H
, Tapanainen
J
, et al The ratios of serum bioactive/immunoreactive luteinizing hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay. J Clin Endocrinol Metab. 1990 Jun;70(6): 1495–505.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
